← Leaderboards
Thomas Anton Dudler
Omeros Corporation
$1,052,057
Attributed
$1,052,057
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $685.4K · FY2010–12$1M$750K$500K$250K$0
'10
'11
'12
Funding mix
By agency
NIH$1,052,057 · 3
By mechanism
R44$660,672 · 1
R43$391,385 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoPathogenesisPersonsTissuesEvaluationBaseMonoclonal AntibodiesPathway InteractionsGovernmentProgramsPreventPre-ClinicalAntibodiesLectinEffective TherapyComplement PathwayMouse ModelKnockout MiceInjuryBlindnessComplementLeftHuman DiseaseGrant
Grant awards (4)
MASP-2 Antibodies for Diabetic Neuropathy$193,002
R43 · FY2012 · NS · contact PI
MASP-2 Therapy for Macular Degeneration$173,661
R44 · FY2011 · EY · contact PI
MASP-2 Therapy for Macular Degeneration$487,011
R44 · FY2010 · EY · contact PI
Development of MASP-2 MoAbs for the treatment of diabetic nephropathy$198,383
R43 · FY2010 · DK · contact PI